Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services | News
Search Refinements

Contract Services News

View news from other Pharmaceutical sectors:
76-90 of 2360 results
IntelGenx, RedHill Biopharma sign deal with Grupo Juste for commercialization of RIZAPORT
IntelGenx and RedHill Biopharma signed a definitive agreement with Grupo Juste for the commercialization of RIZAPORT, a unique oral thin film for the treatment of acute migraines, in the country of Spain.
Contract Research & Services > Contract Services > News
Aeterna Zentaris, Orient EuroPharma sign exclusive license deal for Zoptrex in Taiwan and Southeast Asia
Aeterna Zentaris has signed an exclusive license agreement with Cyntec, an affiliate of OEP (“Cyntec”), for its lead anti-cancer compound, Zoptrex (zoptarelin doxorubicin), for the initial indication of endometrial cancer, for Taiwan and nine countries in Southeast Asia (the “Territory”).
Contract Research & Services > Contract Services > News
BIND Therapeutics files motion for sale of assets after accepting stalking horse bid from Pfizer
BIND Therapeutics has filed a motion for court approval of a stalking horse asset purchase agreement bid from Pfizer for the purchase of the majority of BIND's assets.
Contract Research & Services > Contract Services > News
Clinigen, Horizon Pharma partner to start European Managed Access program for RAVICTI Oral Liquid
Clinigen Group's Idis Managed Access (MA) division and Horizon Pharma have initiated a Managed Access program in Europe for Horizon’s RAVICTI (glycerol phenylbuterate) Oral Liquid.
Contract Research & Services > Contract Services > News
Therapix signs binding MOU with Swiss pharmaceutical firm to receive License to use formulation for ultralow-dosage administration
Therapix Biosciences has entered into a binding memorandum of understandings with a Swiss pharmaceutical development company, to receive a worldwide and exclusive license to use the formulation for sublingual administration of ultralow dosages of THC, for the purpose of developing and marketing the formulation in the indications on which the Company has chosen to focus, with an emphasis on cognitive impairments.
Contract Research & Services > Contract Services > News
Rich Pharmaceuticals retains Theradex Systems to help advance Hodgkin's Lymphoma indication
Rich Pharmaceuticals has entered into an additional agreement with Theradex Systems to assist it in submitting a protocol to the US FDA for Hodgkin's Lymphoma under the company's existing Investigational New Drug Application (IND).
Contract Research & Services > Contract Services > News
Impax Laboratories to buy generic products from Teva and Allergan for $586m
By PBR Staff Writer
Impax Laboratories has agreed to acquire a portfolio of generic drugs from Teva Pharmaceutical Industries and Allergan for about $586m.
Contract Research & Services > Contract Services > News
Cipher Pharmaceuticals out-licenses rights to ASF-1096 for anorectal disorders
Cipher Pharmaceuticals announced that Edesa Biotech has licensed the rights to ASF-1096 (R-salbutamol) for use in anorectal disorders.
Contract Research & Services > Contract Services > News
Sagent Pharmaceuticals to buy product portfolio from Teva Pharmaceutical Industries
Sagent Pharmaceuticals has entered into a definitive agreement with Teva Pharmaceutical Industries and Actavis to acquire a portfolio of five Abbreviated New Drug Applications (ANDAs) in the U.S. for $40m.
Contract Research & Services > Contract Services > News
Clinigen signs global access deal with Galen for chemotherapy drug DaunoXome
By PBR Staff Writer
Clinigen Group has signed a supply agreement with pharmaceutical firm Galen for chemotherapy drug DaunoXome.
Contract Research & Services > Contract Services > News
Faron Pharmaceuticals licenses Traumakine Korean rights to Pharmbio Korea
Faron Pharmaceuticals has entered into a licensing agreement with Pharmbio Korea for the development and commercialisation of Traumakine in Korea.
Contract Research & Services > Contract Services > News
Aspen to buy rights to AstraZeneca’s global anaesthetics portfolio outside US
By PBR Staff Writer
Aspen Global Incorporated (AGI) has agreed to acquire AstraZeneca’s worldwide anaesthetics portfolio, excluding the US, for about $520m.
Contract Research & Services > Contract Services > News
CRISPR gains license to Anagenesis’ P2MCs technology for cell therapy for muscle diseases
CRISPR Therapeutics and Anagenesis Biotechnologies announced a strategic in-licensing and collaboration agreement, which grants CRISPR Therapeutics exclusive worldwide license to Anagenesis’ Paraxial Mesoderm Multipotent Cells (P2MCs) technology for cell therapy for all human muscle diseases.
Contract Research & Services > Contract Services > News
ViiV Healthcare signs public tender deal with Botswana Ministry of Health for dolutegravir
ViiV Healthcare, a global specialist HIV company majority owned by GSK, with Pfizer and Shionogi Limited as shareholders, confirmed a public tender agreement with the Ministry of Health in Botswana to support the implementation of a new national ‘Treat All’ programme which aims to ensure people living with HIV in the country get tested and receive treatment.
Contract Research & Services > Contract Services > News
ARIAD completes sale of European operations and out-license of European rights to Iclusig
ARIAD Pharmaceuticals has completed the sale of its European operations to Incyte and entered into the previously announced license agreement for Incyte to exclusively license Iclusig (ponatinib) in Europe and other select countries.
Contract Research & Services > Contract Services > News
76-90 of 2360 results